A Phase 2 Study of Tigilanol Tiglate in People With Soft Tissue Sarcoma


Full Title

A Phase IIa Open Label Study Evaluating the Preliminary Efficacy of Intratumoural Tigilanol Tiglate in Advanced and/or Metastatic Soft Tissue Sarcoma of the Extremities and Body Wall


In this study, researchers want to learn if tigilanol tiglate is safe and works well against advanced soft tissue sarcoma. When injected into a tumor, tigilanol tiglate stops the blood supply to the cancer, which starves the tumor of nutrients. It may also make the immune system target and kill cancer cells.

Who Can Join

To join this study, there are a few conditions. You must:

  • Have soft tissue sarcoma of the arms, legs, or body wall (exterior of the body, as opposed to internal organs).
  • Have sarcoma that has grown beyond its original location and is in a place where the tumor can be injected.
  • Have completed prior treatment at least 4 weeks before getting tigilanol tiglate.
  • Be able to walk and do routine activities for more than half the time you are awake.
  • Be age 18 or older.


For more information and to see if you can join this study, please contact Dr. Edmund Bartlett’s office at 212-639-2448.




Phase II (phase 2)



ClinicalTrials.gov ID